Navigation Links
String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline
Date:7/28/2014

igate diseases in a variety of unmet needs, including brain tumors. We see our current collaboration with Dr. Sampson and Mitchells’ laboratories as a step in that direction, where we hope to share our knowledge about LAMP and our resources to further enable the potentially breakthrough vaccine work that he is conducting in this devastating disease.”

Classified as a Grade IV astrocytoma, GBM develops from the lineage of star-shaped glial cells called astrocytes, which support nerve cells. GBM are also known as the most aggressive of a group of tumors referred to as high-grade gliomas. Patients with GBM have a poor prognosis and usually survive less than 15 months following diagnosis. The current standard of care consists of surgical debulking (full resection is nearly impossible due to the highly infiltrative nature of the cancerous cells into healthy brain tissue), followed by chemotherapy (temozolomide), and radiation. Currently there are no effective long-term treatments for this disease.

About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit, http://www.immunomix.com.

About National Brain Tumor Society
National Bra
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
2. Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
3. Neuroprotection - Drugs, Markets and Companies - Updated 2013 Report with Extra Company Collaborations
4. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
5. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
6. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
7. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
8. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
11. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... 28, 2015  Moerae Matrix Inc. announced today ... trial with MMI-0100, a first-in-class inhibitor of MAPKAP ... pulmonary disorders characterized by inflammation and fibrosis.  The ... , is a double-blind, two-way cross-over design ... and tolerability of MMI-0100 when given via inhalation ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/28/2015)... RESEARCH TRIANGLE PARK, N.C., July 28, 2015  United ... its financial results for the second quarter ended ... nearly 300% as compared to the second quarter ... said Roger Jeffs, Ph.D., United Therapeutics, President and ... was due to an increase in the number ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , ATLANTA, Oct. 6 CryoLife, Inc., ... and cardiovascular tissue processing company, today announced that it has ... and Drug Administration (FDA) for its CryoValve® SG aortic human ... in obtaining a Humanitarian Device Exemption (HDE) for the CryoValve ...
... , ROCKVILLE, Md., Oct. 6 Novavax, Inc. (Nasdaq: ... Rahul Singhvi, President and CEO of Novavax, will be making ... October 7th, 2009 at the Palais des Congres de Lyon, ... ,Innovative Approaches to RSV vaccine development and VLP based vaccines, ...
... Oct. 6 State, county and local government leaders ... REGN ) and BioMed Realty Trust, Inc. (NYSE: ... new 229,000 square foot corporate headquarters and research facility ... New York. Featured speakers at the ceremony were Leonard ...
Cached Biology Technology:CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 2Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 3Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 4Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview 5
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Genomic research could help doctors better target a drug widely ... by Genomic Health Inc. (Nasdaq: GHDX) and the Translational Genomics ... in colon cancer. It is used in early disease, following ... is also used in advanced disease to slow progression of ...
... were initiated in 1971 and have become a leading ... enzyme technology and biocatalysis, putting an emphasis on emerging ... aspects. The proposed scope and thrust of the ... on new developments in fields including protein design and ...
... report that they are the first to show in molecular ... split up via gene duplication to pursue their ... Proceedings of the National Academy of Sciences , validates a ... also confirms the ancestry of a family of "antifreeze proteins" ...
Cached Biology News:TGen and Genomic Health Inc. discover genes affecting cancer drug 2Researchers show how 1 gene becomes 2 (with different functions) 2Researchers show how 1 gene becomes 2 (with different functions) 3
... 1 outflow Single-cell and patch delivery ... solution change Very small dead volume , ... 360, 250 and 100 micron delivery tips ... micromanipulator Available in 4, 8, and 16 ...
... Racks are ideal for storage and transport ... polypropylene racks withstand extreme temperatures, making them ... may also be autoclaved for use in ... side accommodates 0.5ml microcentrifuge tubes, the other ...
... consists of universal lysis buffer, PCR mix, ... 100 25 l volume PCR reactions. This ... negative or positive rod and coccus bacteria, ... Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and etc. ...
... BacVector Insect Cell Medium is optimized for ... Insect Cells. In this protein-free medium, Sf9 ... * 107 cells/ml with viabilities above 95%. ... assays, where color from X-gluc staining of ...
Biology Products: